DelveInsight Business Research LLP

DelveInsight's "Porphyria Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Porphyria, historical and forecasted epidemiology as well as the Porphyria market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.The Porphyria market report provides current treatment practices, emerging drugs, Porphyria market share of the individual therapies, and current and forecasted Porphyria market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Porphyria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Porphyria market.

Porphyria Overview

Porphyrias are a group of rare inherited blood disorders. People with these disorders have problems making a substance called heme in their bodies. Heme is made of body chemicals called porphyrin, which is bound to iron. Heme is a component of hemoglobin, a protein in red blood cells that carries oxygen. Acute porphyrias result from a deficiency of certain enzymes in the heme biosynthetic pathway, resulting in the accumulation of heme precursors that cause intermittent attacks of abdominal pain and neurologic symptoms. Attacks are precipitated by certain medications and other factors. Diagnosis is based on elevated levels of the porphyrin precursors delta-aminolevulinic acid and porphobilinogen in the urine during attacks. Attacks are treated with glucose or if more severe, IV heme. Symptomatic treatment, including analgesia, is given as necessary.

Porphyria Epidemiology Insights:

• The incidence of Porphyrias is different in the clinical setting, but its incidence rate ranges from 4% to 38% in hospitalization wards and the mortality rate due to Porphyrias and its associated secondary complications among the elderly is approximately 68%. A study in an elderly care home in Hapan showed that more than 91% of the total study population had Porphyrias at various intensities.

•  In the USA, about $11 billion is spent annually by the healthcare system for the prevention and treatment of Porphyrias. In the UK, 4% of the total treatment costs are allocated for the treatment of Porphyrias. In addition to the extra costs spent on the treatment of Porphyrias, there is bed reservation and associated costs arising from hospitalization.

Porphyria Epidemiology Segmentation

• Total Porphyria prevalent cases 

• Total  Porphyria incident cases 

• Total Porphyria diagnostic cases 

• Total Porphyria treatment cases 

Porphyria Market Outlook 

The Porphyrias market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Porphyrias market trends by analyzing the impact of current Porphyrias therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Porphyrias market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Porphyrias market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Porphyrias market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Porphyria Market Trends

Porphyria Key Companies

• Alynylm Pharmaceuticals 

• Novartis Pharmaceuticals 

• Cycle Pharmaceuticals 

• Mitsubishi Tanabe Pharmaceuticals 

• And many others 

 Porphyria Therapies 

• Givosiran (ALN-AS1)

• Deferasirox

• Exjade

• Hemin

And many others 

 Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of Porphyria

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  The United States 

7.  EU 5

8.  Porphyria Emerging Therapies

9.  Porphyria Market Outlook

10.  Market Access and Reimbursement of Therapies

11.  Market Drivers 

12.  Market Barriers 

13.  Appendix

14.  Porphyria Report Methodology

15.  DelveInsight Capabilities

16.  Disclaimer

Click here to read more about Porphyria Market Trends

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services